Genome & Company (KOSDAQ:314130)
South Korea · Delayed Price · Currency is KRW 6,660.00
-250.00 (-3.62%)
At close: Apr 9, 2026
Genome & Company Revenue
In the year 2025, Genome & Company had annual revenue of 24.59B KRW, down -11.38%. Genome & Company had revenue of 5.87B in the quarter ending December 31, 2025, a decrease of -18.89%.
Revenue
24.59B
Revenue Growth
-11.38%
P/S Ratio
9.39
Revenue / Employee
n/a
Employees
n/a
Market Cap
230.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 24.59B | -3.16B | -11.38% |
| Dec 31, 2024 | 27.74B | 13.45B | 94.07% |
| Dec 31, 2023 | 14.30B | 211.39M | 1.50% |
| Dec 31, 2022 | 14.08B | 13.63B | 3,021.27% |
| Dec 31, 2021 | 451.25M | 300.66M | 199.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ISU Abxis | 56.67B |
| NIBEC | 32.72B |
| Prestige Biologics | 19.24B |
| S.Biomedics | 16.55B |
| Bio Solution | 15.20B |
| TiumBio | 12.29B |
| Kangstem Biotech | 3.57B |
| NovMetaPharma | 1.30B |